The effect of dopamine agonist on aromatase gene expression in ovary of estradiol valerate-induced polycystic ovary syndrome in Wistar rat

Polycystic Ovary Syndrome is one of the common endocrine disorders in women caused by an increase in testosterone. Aromatase enzyme decreases testosterone. In the present study, the effect of drug Pramipexol as dopamine agonist in three doses and two different times on ovarian aromatase gene expression in Wistar PCOS rats was investigated.

Thirty mice were divided to two groups (n = 15) including three subgroups of solvent, PCOS (injection of 2 mg of Estradiol valerate), and PCOS + drug (1, 2, 4 mg/kg). Pramipexol was administered 15 or 30 days after induction of PCOS, as group 1 or 2, for 14 days. Aromatase gene expression was then measured, and analyzed by One-way ANOVA analysis of variance and Tukey's post hoc test.

The results showed an increase in aromatase gene expression in the subgroups receiving the drug (p < 0.05, p < 0.01, p < 0.001) in each of the two study groups. There was significant difference between 2 groups in gene expression after drug treatment by 2, and 4 mg/kg (p < 0.01, p < 0.05).

Pramipexol doses 1, 2, 4 mg/kg increased the expression of the ovarian aromatase gene in PCOS mice in a time and dose-dependent manner. Pramipexol 4 mg/kg, 15 days after induction of PCOS caused the greatest increase in aromatase gene expression and can be suggested to improve PCOS.
‎